Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
published its annual social impact report, highlighting
achievements related to the two pillars that drive the Company’s
initiatives: building healthy communities and leading a responsible
business.
Teva’s 2017 Social Impact Report spotlights the company’s
commitment to corporate responsibility and transparency, and
provides context on its efforts to contribute to healthy
communities in ways the business can uniquely support—through safe
medicines, collaboration, health initiatives and innovative
research. The report also presents six new corporate positions and
policies, establishing the company’s commitment to donations, human
rights, diversity and inclusion, occupational health and safety,
the environment and antimicrobial resistance.
“Since joining the company late last year, I have been motivated
by the opportunity to advance our legacy of promoting health.
Operating as an ethical, enduring enterprise is critical to
continue bringing value to our business, our stakeholders and
society,” said Kåre Schultz, President and CEO of Teva. “Social
Impact is inherently embedded in our brand, as Teva is uniquely
positioned to improve health by offering accessible treatments to
millions worldwide.”
Teva also outlined progress on its signature initiative to
address the challenges of non-communicable diseases by uncovering
solutions to multiple chronic conditions (MCC) with the release of
an independent research report, Multiple Chronic Conditions: The
Global State, in 2017. The report quantifies health, economic and
personal challenges of patients with MCC and the burden on
communities and systems.
“We are continuing to focus on engagement with patients,
caregivers and communities, ensuring we communicate with them in a
cohesive way, and this is a central element of our social impact
efforts,” said Iris Beck-Codner, Teva’s Executive Vice President,
Global Brand & Communications. “These activities bring our new
brand promise to life, enabling people to live better days, and
support our goal to make the world a healthier place.”
Contributing to healthy communities
As part of Teva’s ongoing efforts to contribute to healthy
communities in 2017, Teva invested $1.8B in R&D, contributed
$82.3M across more than 25 countries through donations, patient
assistance and community involvement, and funded more than $350,000
of research on genetic disorders and autism brain mechanisms.
Additional efforts included the support of 80 patient programs in
38 countries, reaching more than 300,000 people and convening 17
patient groups via the Improving Health Global Patient Advocacy
Dialogue. Finally, Teva assembled global health leaders to discuss
potential solutions to MCC at the World Economic Forum Sustainable
Development Impact Summit.
Leading a responsible business
Teva has conducted its business with integrity through
investments such as $120M in a global program to make medicines at
38 facilities counterfeit-compliant ahead of anticipated regulatory
changes, and a $20.3M investment in 87 energy-efficiency projects,
which yielded annualized electricity savings, while reducing
greenhouse gas emissions by 16,700 tons.
Carlo de Notaristefani, Teva’s Executive Vice President, Global
Operations, added, “For Teva, social impact is rooted in
responsible business and manufacturing practices. This work
includes ensuring transparency and compliance in our operations,
protecting the environment and supporting our employees and the
places we call home. It also encompasses efforts focused on
improving patient lives and increasing access to healthcare,
working together with partners across sectors.”
To view the 2017 Social Impact Report, visit here or to learn
more about Teva’s Social Impact efforts online, click here.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients
every day. Headquartered in Israel, Teva is the world’s largest
generic medicines producer, leveraging its portfolio of more than
1,800 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong
portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development
division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2017 were $22.4 billion. For
more information, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to:
- our ability to successfully compete in
the marketplace, including: that we are substantially dependent on
our generic products; competition for our specialty products,
especially COPAXONE®, our leading medicine, which faces competition
from existing and potential additional generic versions and
orally-administered alternatives; competition from companies with
greater resources and capabilities; efforts of pharmaceutical
companies to limit the use of generics including through
legislation and regulations; consolidation of our customer base and
commercial alliances among our customers; the increase in the
number of competitors targeting generic opportunities and seeking
U.S. market exclusivity for generic versions of significant
products; price erosion relating to our products, both from
competing products and increased regulation; delays in launches of
new products and our ability to achieve expected results from
investments in our product pipeline; our ability to take advantage
of high-value opportunities; the difficulty and expense of
obtaining licenses to proprietary technologies; and the
effectiveness of our patents and other measures to protect our
intellectual property rights;
- our substantially increased
indebtedness and significantly decreased cash on hand, which may
limit our ability to incur additional indebtedness, engage in
additional transactions or make new investments, and may result in
a further downgrade of our credit ratings; and our inability to
raise debt or borrow funds in amounts or on terms that are
favorable to us;
- our business and operations in general,
including: failure to effectively execute the restructuring plan
announced in December 2017; uncertainties related to, and failure
to achieve, the potential benefits and success of our senior
management team and organizational structure; harm to our pipeline
of future products due to the ongoing review of our R&D
programs; our ability to develop and commercialize additional
pharmaceutical products; potential additional adverse consequences
following our resolution with the U.S. government of our FCPA
investigation; compliance with sanctions and other trade control
laws; manufacturing or quality control problems, which may damage
our reputation for quality production and require costly
remediation; interruptions in our supply chain; disruptions of our
or third party information technology systems or breaches of our
data security; the failure to recruit or retain key personnel;
variations in intellectual property laws that may adversely affect
our ability to manufacture our products; challenges associated with
conducting business globally, including adverse effects of
political or economic instability, major hostilities or terrorism;
significant sales to a limited number of customers in our U.S.
market; our ability to successfully bid for suitable acquisition
targets or licensing opportunities, or to consummate and integrate
acquisitions; and our prospects and opportunities for growth if we
sell assets;
- compliance, regulatory and litigation
matters, including: costs and delays resulting from the extensive
governmental regulation to which we are subject; the effects of
reforms in healthcare regulation and reductions in pharmaceutical
pricing, reimbursement and coverage; governmental investigations
into sales and marketing practices; potential liability for patent
infringement; product liability claims; increased government
scrutiny of our patent settlement agreements; failure to comply
with complex Medicare and Medicaid reporting and
payment obligations; and environmental risks;
- other financial and economic risks,
including: our exposure to currency fluctuations and restrictions
as well as credit risks; potential impairments of our intangible
assets; potential significant increases in tax liabilities; and the
effect on our overall effective tax rate of the termination or
expiration of governmental programs or tax benefits, or of a change
in our business;
and other factors discussed in our Annual Report on Form 10-K
for the year ended December 31, 2017, including in the section
captioned “Risk Factors,” and in our other filings with the U.S.
Securities and Exchange Commission, which are available at
www.sec.gov and www.tevapharm.com. Forward-looking statements speak
only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180717005449/en/
Teva Pharmaceutical Industries Ltd.IR ContactsUnited
StatesKevin C. Mannix, 215-591-8912orIsraelRan Meir, 972
(3) 926-7516orTomer Amitai, 972 (3) 926 7656PR ContactsUnited
StatesElizabeth DeLuca, 267-468-4329orIsraelYonatan
Beker, 972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024